🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Florida
Clinical trial register · United States · industry-sponsored

Clinical Trials in Florida, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca173 Eli Lilly and Company150 Merck Sharp & Dohme LLC116 AbbVie112 Novartis Pharmaceuticals107
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Florida

4401 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain
NCT06912646Neuropathy, Neuropathy;Peripheral
Erchonia Corporation
Not applicable
32
Florida
2025-05-01
Recruiting
Evaluation of Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stones, A Pivotal Trial
NCT06942949Kidney Calculi; Ureteral Calculi
Avvio Medical
Not applicable
101
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Minnesota
2025-05-01
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435Hypertension, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
DrugsPelacarsen·Inclisiran
Novartis Pharmaceuticals
Phase 3
340
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Active, closed
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530Hypertension
DrugOrforglipron
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
NCT06907043Advanced Solid Tumors
Eikon Therapeutics
Phase 1/2
130
Colorado, Florida, Massachusetts, Texas, Virginia
2025-04-30
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT06884618Neoplasms
Hoffmann-La Roche
Phase 1
405
California, Colorado, Connecticut, Florida, Texas
2025-04-30
Recruiting
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919Muscular Diseases, Neuromuscular Manifestations, Autoimmune, Autoimmune Diseases
Arcellx, Inc.
Phase 1
30
California, Florida, Michigan, Minnesota, New York, Ohio, Oregon, Pennsylvania
2025-04-30
Recruiting
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
NCT06538064Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Takeda
Observational
30
California, Connecticut, Florida, Hawaii, Illinois, Kansas, North Carolina
2025-04-29
Recruiting
Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
NCT06963281Solid Tumors
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 1
285
Arizona, Florida, Minnesota, New York, Texas
2025-04-29
Active, closed
Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06747468Post Bariatric Hypoglycemia
Amylyx Pharmaceuticals Inc.
Phase 3
75
California, Colorado, Florida, Georgia, Kansas, Massachusetts, New York, North Carolina
2025-04-29
Recruiting
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320Generalized Anxiety Disorder (GAD)
DrugABBV-932
AbbVie
Phase 2
315
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-04-29
Recruiting
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
NCT06394869Hematuria - Cause Not Known
Pacific Edge Limited
Not applicable
1,000
Alabama, California, Florida, Indiana, Louisiana, Maryland, New Jersey, New York
2025-04-29
Recruiting
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085Lymphoma
DrugsGlofitamab·Tocilizumab·Obinutuzumab·Oxaliplatin
Hoffmann-La Roche
Phase 1
50
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Maryland, New Mexico
2025-04-28
Recruiting
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
NCT06746883Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Innoviva Specialty Therapeutics
Observational
100
California, Florida, Kansas, Kentucky, Louisiana, New York, Ohio, Pennsylvania
2025-04-28
Recruiting
A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.
NCT06632600Chagas Disease
Novartis Pharmaceuticals
Phase 2
130
California, Florida, Massachusetts, Texas
2025-04-28
Recruiting
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177Cancer Weight Loss
Endevica Bio
Phase 2
120
Arizona, California, Florida, Georgia, Illinois, Kansas, Michigan, Nebraska
2025-04-28
Recruiting
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
NCT06533761AML, Adult, MDS
DrugCytarabine
Stelexis BioSciences
Phase 1
125
California, Colorado, Florida, Massachusetts, Missouri, New York, Ohio, Texas
2025-04-28
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, Ohio, Pennsylvania
2025-04-28
Active, closed
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
NCT06881836Alzheimer Disease
Ono Pharmaceutical Co., Ltd.
Phase 2
260
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Kansas
2025-04-24
Recruiting
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463Metastatic Colorectal Cancer
DrugsPanitumumab·Telisotuzumab Adizutecan·Leucovorin·Oxaliplatin
AbbVie
Phase 2
390
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2025-04-24
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Alabama, Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois
2025-04-24
Recruiting
Clinical Investigation of MAIA Microperimeter Device: Mesopic Normative Database Collection
NCT06991127Healthy Eyes
Centervue SpA
Not applicable
380
Florida
2025-04-23
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
DrugPumitamig
BioNTech SE
Phase 1/2
380
California, Florida, Georgia, Illinois, Michigan, Missouri, New Jersey, New York
2025-04-23
Active, closed
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142Sjogren Disease
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, New York, North Carolina
2025-04-23
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
Vanda Pharmaceuticals
Phase 3
420
Alabama, Arizona, California, Florida, Georgia, Illinois, Massachusetts, Montana
2025-04-21
Recruiting
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930Lupus Erythematosus, Systemic
DrugsAZD0120·Fludarabine·Cyclophosphamide
AstraZeneca
Phase 1/2
150
California, Florida, Georgia, Illinois, Maryland, Massachusetts, Missouri, New York
2025-04-21
Active, closed
Pivotal Study of Voro Urologic Scaffold
NCT06873581Radical Prostatectomy, Stress Urinary Incontinence (SUI)
Levee Medical, Inc.
Phase 3
266
Arizona, California, Florida, Illinois, Indiana, Maryland, Mississippi, New York
2025-04-18
Active, closed
EluPro Antibiotic-Eluting BioEnvelope Registry
NCT06854081Cardiac Arrhythmias
Elutia Inc.
Observational
100
California, Florida, Massachusetts, Pennsylvania
2025-04-17
Recruiting
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
NCT06909214New Onset Generalized Myasthenia Gravis (gMG)
DrugEfgartigimod PH20
argenx
Phase 4
30
California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Michigan, Ohio
2025-04-17
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Alabama, California, Colorado, Florida, Georgia, Kansas, Maryland, Minnesota
2025-04-17
Recruiting
Fertilo In Vitro Research Study and Trial
NCT06858111In Vitro Maturation of Oocytes
Gameto, Inc.
Phase 3
500
California, Florida, Maryland, New York, North Carolina, Texas, Utah
2025-04-17
Recruiting
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
NCT06855160Chickenpox
GlaxoSmithKline
Phase 3
911
Arizona, California, Florida, Idaho, Ohio, Texas, Virginia
2025-04-17
Active, closed
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
NCT06907511Pandemic Influenza Immunization, Healthy Volunteers
Sanofi
Phase 1/2
720
California, Florida, Georgia, Michigan, Nebraska, Ohio, South Carolina, Texas
2025-04-17
Active, closed
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080Diabetic Macular Edema (DME)
DrugsEYE103·Ranibizumab
EyeBiotech Ltd.
Phase 2/3
1,054
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-04-16
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky, Nebraska
2025-04-16
Recruiting
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
NCT06866405RSV Infection
DrugRSVpreF
Pfizer
Phase 3
550
Alabama, Arizona, California, Colorado, Florida, Idaho, Iowa, Kansas
2025-04-16
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
850
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts
2025-04-16
Recruiting
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06795412Advanced Solid Tumors
DrugsPYX-201·Pembrolizumab
Pyxis Oncology, Inc
Phase 1/2
220
California, Florida, Illinois, Massachusetts, New York, Oklahoma, Pennsylvania, Texas
2025-04-15
Active, closed
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226Plaque Psoriasis
DrugsIcotrokinra·Ustekinumab
Janssen Research & Development, LLC
Phase 3
752
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa
2025-04-15
Recruiting
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
NCT06893588Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Vesalio
Observational
200
California, Connecticut, Florida, Georgia, Illinois, Iowa, Kentucky, Maine
2025-04-14
Active, closed
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
NCT06941844Major Depressive Disorder
DrugDT120
Definium Therapeutics US, Inc.
Phase 3
149
Arkansas, California, Colorado, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-04-14
Recruiting
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06673017Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
PanTher Therapeutics
Phase 1
26
California, Florida, Michigan, New York, Texas, Washington
2025-04-14
Active, closed
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
NCT06891066Human Immunodeficiency Virus Type 1 (HIV-1) Infection
DrugBIC/FTC/TAF
Merck Sharp & Dohme LLC
Phase 2
150
California, District of Columbia, Florida, Georgia, Missouri, North Carolina, Texas
2025-04-14
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Alabama, Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida
2025-04-11
Active, closed
ASCEND CSP IDE Study
NCT06830746Heart Failure, Ventricular Arrythmia
Abbott Medical Devices
Not applicable
414
Alabama, Arizona, Arkansas, California, District of Columbia, Florida, Massachusetts, New York
2025-04-11
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06865105Psoriatic Arthritis
DrugsLutikizumab·Risankizumab
AbbVie
Phase 2
120
California, Florida, Illinois, Maryland, Ohio, Pennsylvania, Tennessee, Texas
2025-04-11
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
DrugsRilvegostomig·Pembrolizumab
AstraZeneca
Phase 3
830
California, Delaware, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2025-04-10
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671CLL, Chronic Lymphocytic Leukemia
DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax
BeOne Medicines
Phase 3
250
Arkansas, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2025-04-10
Recruiting
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
869
California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland, Michigan
2025-04-09
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
DrugsCDK4/6i·Inavolisib·Letrozole
Hoffmann-La Roche
Phase 3
450
Arizona, California, Florida, Georgia, Illinois, Kentucky, Maryland, Michigan
2025-04-09
Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
NCT06920043Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
GlaxoSmithKline
Phase 2
42
Arizona, California, Florida, Georgia, Maryland, Missouri, New York, North Carolina
2025-04-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
DrugsMvasi·Steroid mouthwash (dexamethasone·Sac-TMT·Acetaminophen
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-04-09
Recruiting
Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)
NCT06556654Breast Reconstruction Surgery
W.L.Gore & Associates
Not applicable
180
Arizona, California, Florida, Illinois, Kansas, Maryland, Michigan, Mississippi
2025-04-09
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
DrugClemizole HCl
Epygenix
Phase 3
260
Arkansas, California, Florida, Illinois, Kentucky, Michigan, Minnesota, Nebraska
2025-04-09
Active, closed
Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection
NCT06621251Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee
Trellis Bioscience LLC
Phase 2
60
Arizona, California, Florida, Maryland, Massachusetts, New York, North Carolina, Texas
2025-04-08
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
DrugsFingolimod·Ozanimod
Bristol-Myers Squibb
Phase 3
194
California, Florida, Illinois, Kentucky, New Jersey, Ohio, Oregon, Texas
2025-04-08
Active, closed
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850Hidradenitis Suppurativa
DrugBimekizumab
UCB Biopharma SRL
Phase 3
43
Arizona, California, District of Columbia, Florida, Kentucky, Michigan, North Carolina, Ohio
2025-04-07
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165ALS
Amylyx Pharmaceuticals Inc.
Phase 1
48
California, District of Columbia, Florida, Massachusetts, Minnesota, Pennsylvania, Tennessee, Texas
2025-04-07
Recruiting
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
NCT06708299Recurrent Pericarditis
Cardiol Therapeutics Inc.
Phase 3
110
Arizona, California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York
2025-04-07
Active, closed
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
NCT06868264HEPATITIS C VIRUS CHRONIC INFECTION
DrugsBEM/RZR·Bemnifosbuvir-Ruzasvir·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-04-07
Active, closed
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
NCT06973720Obesity, Overweight or Obesity
DrugPF-08653944
Pfizer
Phase 2
268
Florida, Georgia, New Jersey
2025-04-07
Active, closed
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT06459869Locally Advanced Rectal Cancer (LARC)
Akamis Bio
Phase 1
30
California, Florida, Missouri, Ohio, Texas
2025-04-07
Recruiting
Effect of Patiromer in Children Under 12 Years of Age With High Blood Potassium Levels
NCT05766839Hyperkalemia
Vifor Pharma, Inc.
Phase 2
36
Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, New York, North Carolina
2025-04-06
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Recruiting
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC)
DrugsAmrubicin·Lurbinectedin·Topotecan·Sacituzumab Govitecan
Gilead Sciences
Phase 3
695
Alaska, Arkansas, California, Florida, Illinois, Indiana, Kentucky, Maine
2025-04-04
Active, closed
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
NCT06910358Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
DrugDISC-1459
Disc Medicine, Inc
Phase 3
183
California, Florida, Massachusetts, Michigan, New York, North Carolina, Ohio, Texas
2025-04-04
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington
2025-04-03
Active, closed
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
NCT07108166COPD, Smoking, Tobacco Use
Philip Morris Products S.A.
Not applicable
290
Florida, Georgia, Texas
2025-04-02
Active, closed
Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea
NCT06776432Sleep Apnea
Shionogi
Phase 2
60
California, Florida, Massachusetts, Michigan, Minnesota, Ohio, South Carolina, Texas
2025-04-02
Recruiting
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
NCT06615050Graft-versus-host Disease (GVHD)
DrugsMycophenolate Mofetil·Tacrolimus·Methotrexate·Ruxolitinib
Incyte Corporation
Phase 3
572
California, Florida, Georgia, Indiana, Kansas, Massachusetts, Michigan, Missouri
2025-04-02
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945Alopecia Areata
DrugRitlecitinib
Pfizer
Phase 3
674
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-04-01
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961Atopic Dermatitis
DrugAfimkibart
Hoffmann-La Roche
Phase 2
162
California, Florida, Georgia, Indiana, Michigan, Minnesota, New Jersey, New York
2025-04-01
Active, closed
TECTONIC CAD IVL IDE Study
NCT06885177Coronary Artery Calcification, Coronary Artery Disease, Stenotic Coronary Lesion
Abbott Medical Devices
Not applicable
335
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2025-04-01
Active, closed
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
NCT06864169Gastrointestinal Cancer
DrugsRaludotatug Deruxtecan·R-DXd
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Recruiting
Pulsed Electromagnetic Field Treatment With Dementia Patients
NCT06862557Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Herrick Medical LLC
Not applicable
48
Florida
2025-04-01
Recruiting
Tissue Repair Gel in Venous Leg Ulcers in AU/US
NCT06707103Venous Leg Ulcer, Venous Ulcer, Venous Stasis Ulcer, Venous Stasis
DrugTR987
TR Therapeutics
Phase 3
312
Florida, Michigan, New York, Texas
2025-04
Active, closed
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
NCT06807463Celiac Disease
DrugTEV-53408
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
50
California, Colorado, Florida, Georgia, Louisiana, Michigan, Minnesota, New York
2025-03-31
By invitation
Software Validation Study-Cognitive Status Indicator
NCT06809725Alzheimer Disease, Mild Cognitive Impairment, Dementia
Spark Neuro Inc.
Not applicable
600
Florida
2025-03-31
Recruiting
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
NCT06592638Small Cell Lung Cancer
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
30
California, Florida, Kentucky, Ohio, Texas
2025-03-31
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
DrugsBBO-10203·MFOLFIRINOX·MFOLFOX6·Nab-paclitaxel
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
NCT07219927Parkinson Disease
Supernus Pharmaceuticals, Inc.
Observational
120
California, Florida, New York
2025-03-31
Recruiting
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
200
Alabama, Arkansas, California, Florida, Georgia, Massachusetts, Missouri, New York
2025-03-31
Recruiting
MagDI U.S. Registry
NCT06928545Anastomosis, Surgical, Internal Hernia, Bowel Obstruction
GT Metabolic Solutions, Inc.
Observational
106
California, Florida, Kentucky, Louisiana, North Carolina, Washington
2025-03-28
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475Type 2 Diabetes
Eli Lilly and Company
Phase 2
200
Arizona, California, Florida, Georgia, Idaho, Indiana, New Jersey, New York
2025-03-28
Recruiting
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
NCT06750289Eosinophilic Asthma
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Florida, Michigan, Nevada, New Jersey, New York
2025-03-28
Active, closed
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
NCT06869187Bipolar Disorder Depression
DrugABX-002
Autobahn Therapeutics, Inc.
Phase 2
35
California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington
2025-03-28
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
DrugSAR441566
Sanofi
Phase 2
204
Arizona, Connecticut, Florida, Illinois, Michigan, New York, Ohio, Pennsylvania
2025-03-28
Recruiting
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
NCT06581328Ulcerative Colitis, Crohn's Disease
DrugVedolizumab
Takeda
Phase 4
200
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-03-27
Recruiting
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant
DrugsZiftomenib·Imatinib
Kura Oncology, Inc.
Phase 1
157
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-03-27
By invitation
Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair
NCT07224555Hair Thinning
Restore Biologics Holdings, Inc. dba Xtressé
Not applicable
60
Florida, Georgia, Maryland, Washington
2025-03-27
Active, closed
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06818812Solid Tumors
DrugsGEMNabP·MFOLFIRINOX·Pemetrexed
Incyte Corporation
Phase 1
30
California, Colorado, District of Columbia, Florida, Maryland, New Jersey, Pennsylvania, Tennessee
2025-03-27
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598Carcinoma, Non-Small-Cell Lung
DrugsOlomorasib·Durvalumab·Pembrolizumab
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
A Pivotal Study to Evaluate the Effectiveness of Isometric Handgrip Therapy in Elevated Blood Pressure and Hypertensive Subjects
NCT06843577Elevated Blood Pressure, Hypertension
Zona Health, Inc
Not applicable
160
California, Florida, Illinois, Kentucky, Pennsylvania, Tennessee, Texas
2025-03-27
Recruiting
The Pivotal Study of RapidPulseTM Aspiration System
NCT06029491Acute Ischemic Stroke
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112Endometrial Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Carboplatin·Pembrolizumab
AstraZeneca
Phase 3
600
Arizona, Arkansas, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-03-27
Active, closed
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
NCT06745284Obesity
DrugsSurvodutide·Semaglutide
Boehringer Ingelheim
Phase 1
64
Florida, Louisiana
2025-03-26
Recruiting
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785Advanced Solid Tumor
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Rows per page Showing 1501–1600 of 4401
Previous 14 15 16 17 18 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/florida?page=16

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4,401 of those studies with a site in Florida.

How many clinical trials are recruiting in Florida?

2,364 of the 4,401 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 103 have not yet opened recruitment, 1,825 are active but closed to new participants, and 109 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.